Zacks Investment Research disclosed Selecta Biosciences Inc (NASDAQ:SELB), hiking its stock price target to $15.00 earlier today
- Updated: September 20, 2016
Zacks Investment Research bumped the target stock price of Selecta Biosciences Inc (NASDAQ:SELB) to $15, reporting a possible upside of 0.13%.
Only yesterday Selecta Biosciences Inc (NASDAQ:SELB) traded 1.30% higher at $13.25. The company’s 50-day moving average is $12.32 and its 200-day average is $12.88. With the last close up 2.86% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Volume of trade was down over the average, with 3,852 shares of SELB changing hands under the typical 38,160 shares..
Recent Performance Graph:
With a market capitalization of $0.0, Selecta Biosciences Inc has a price-earnings of 0 with a 52 week low of $10.26 and a 52 week high of $16.32.
More About Selecta Biosciences Inc (NASDAQ:SELB)
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company uses synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. It operates in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases segment. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. Its SVP technology has a range of applications to both manage biologic drugs and enable therapies. It offers product candidates in programs, including SVP for immune tolerance and SVP for immune stimulation. Its SVP for immune stimulation includes Smoking cessation and relapse prevention (SEL-070), and and human papillomavirus (HPV)-associated cancer (SEL-701).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.